Genetically engineered cellular nanoparticles loaded with curcuminoids for cancer immunotherapy

Area of Science:

• Biotechnology
• Nanomedicine
• Cancer Immunotherapy

Background:

• Inducing immunogenic cell death (ICD) is crucial for boosting immune responses in immune checkpoint blockade (ICB) therapy.
• Current limitations exist in platforms that integrate ICD and ICB therapies for clinical application.

Purpose of the Study:

• To develop a novel platform for synergistic ICD and ICB therapy to enhance cancer immunotherapy.
• To evaluate the efficacy of genetically engineered nanovesicles loaded with curcumin and targeting PD1.

Main Methods:

• Development of programmed cell death protein 1 (PD1)-overexpressing genetically engineered nanovesicles (NVs) coated with curcumin (Cur)-loaded poly (lactic-co-poly-polyglycolic acid) nanoparticles (PD1@Cur-PLGA).
• Evaluation of tumor targeting, PD1/PDL1 pathway blockade, ICD induction, and immune cell infiltration in tumor models.

Main Results:

• Genetically engineered NVs improved tumor targeting and PD1/PDL1 pathway blockade, stimulating anti-tumor immunity.
• Curcumin effectively induced ICD by modulating apoptotic signaling pathways.
• The combined therapy enhanced intratumoral infiltration of dendritic cells and CD8+ T cells, significantly inhibiting tumor growth in mouse models.

Conclusions:

• The developed PD1@Cur-PLGA nanovesicles offer a synergistic approach to ICD and ICB therapy.
• This strategy provides a low-cost, safe, and effective method for enhancing cancer immunotherapy.
• The platform shows promise for improving treatment outcomes in breast and prostate cancer models.